Business
Hoth Therapeutics Announces the Appointment of Michael Peters, Ph.D. to Scientific Advisory Board
NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has
About this update from Hoth Therapeutics, Inc.
[{"type":"text","content":"NEW YORK, May 22, 2020 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced that Michael H. Peters, Ph.D., has joined the company's Scientific Advisory Board. Dr. Peters is the inventor of Hoth's newly licensed Novel Peptide COVID-19 Therapeutic, to prevent spike protein binding, which may be a leading cause of COVID-19, and could potentially slow its transmission. Dr. Peters is also a recent recipient of COVID-19 Rapid Research Funding sponsored by the Office of the Vice President for Research and Innovation and the C. Kenneth and Dianne Wright Center for Clinical and Translational Research.\n\n \n \n \n \n \n \n\n \nMr. Robb Knie, CEO of Hoth Therapeutics, commented, \"On behalf of the entire team at Hoth, we are pleased to welcome Michael Peters to our Scientific Advisory Board. His acute insight and research experience will be an invaluable asset to us.\" \nDr. Peters currently serves as a member of the Developmental Therapeutics research program at VCU Massey Cancer Center and professor in the Department of Chemical and Life Science Engineering at the VCU College of Engineering. \nAbout Hoth Therapeutics, Inc.\nHoth Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing new generation therapies for dermatological disorders. Hoth's pipeline has the potential to improve the quality of life for patients suffering from indications including atopic dermatitis, chronic wounds, psoriasis, asthma and acne. Hoth has also recently entered into two different agreements to further the development of two different vaccine prospects to prevent or treat COVID-19. To learn more, please visit www.hoththerapeutics.com.\nForward Looking Statements\nThis press release includes \"forward-looking statements\" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements that relate to the joint venture and the preclinical development of the novel peptide technology for COVID-19 and the potential development of products related to COVID-19 and other information that is not historical information. When used herein, words such as \"anticipate,\" \"being,\" \"will,\" \"plan,\" \"may,\" \"continue,\" and similar expressions are intended to identify forward-looking st...